Skip to content

Effects of exercise intervention on cognitive function in breast cancer patients undergoing chemotherapy

Construction and implementation of whole-course bone safety management intervention program for breast cancer patients

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072156
Enrollment
Unknown
Registered
2023-06-05
Start date
2023-01-31
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Expeirment group:exercise management program
Control group:routine care

Sponsors

Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: ? Female, 18 years old = age = 65 years old; ? Breast cancer diagnosed by pathology, stage I~III; ? Patients receiving chemotherapy for the first time after surgery; ? Able to read and understand the disease, and give informed consent , voluntary participation; ?Those with high-risk factors confirmed by the risk prediction model constructed earlier; ?(baseline level) physical activity level is lower than the recommended level of 150 minutes of moderate-intensity exercise per week; ?patients have normal physical activity and muscle strength, and can complete Exercise program; ? Eastern Cooperative Oncology Group (ECOG) physical status score is 0 or 1 and has not deteriorated in the last 2 weeks, and the minimum expected survival is 12 weeks.

Exclusion criteria

Exclusion criteria: ?Symptomatic spinal cord compression or brain metastases; ?Any serious or poorly controlled systemic disease, such as poorly controlled hypertension, hyperglycemia, active bleeding-prone constitution or active infection; ?Combined neurological diseases (such as Acute and chronic brain injury, Alzheimer's disease, etc.); ?Patients with previous mental illness or taking antipsychotic drugs; ?Patients who already had cognitive dysfunction when entering chemotherapy after baseline assessment; ?Have received neoadjuvant chemotherapy before surgery ?Abnormal heart function: there has been a history of severe ventricular arrhythmia and cardiac insufficiency in the past, and there are abnormalities in the electrocardiogram examination in hospital, which is consistent with any of the following heart examination results: a. The resulting average corrected QT interval (QTc) > 470msec, and the Fridericia formula was used for QT interval correction (QTcF); b. Resting ECG suggests that there are various clinically significant rhythm, conduction, or ECG morphological abnormalities (such as complete Left bundle branch block, 3rd degree atrioventricular block, 2nd degree atrioventricular block and PR interval > 250 msec); c. There are any factors that increase the risk of QTc prolongation or arrhythmic events, such as heart failure, Hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death of immediate family members under the age of 40 or any concomitant drugs that prolong the QT interval; d. Left ventricular ejection fraction (LVEF) = 40 %; ?Patients with autoimmune system diseases (such as systemic lupus erythematosus) or exercise contraindications (such as severe osteoporosis, severe motor system diseases); ?Persons with other conditions that are considered unsuitable for exercise by the attending physician or nurse in charge.

Design outcomes

Primary

MeasureTime frame
Cognitive function (subjective function);Cognitive function (objective function);

Secondary

MeasureTime frame
sleep quality;cancer related fatigue;anxiety;depression;quality of life;

Countries

China

Contacts

Public ContactLiu June

Capital Medical University

liujune66@ccmu.edu.cn+86 185 0013 6128

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026